The initial assays will include a respiratory panel for diagnosing respiratory infections, two panels for diagnosing virus- and parasite-based gastrointestinal infections and a panel for differentially diagnosing meningitis.
BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), plans to fully integrate these in vitro diagnostic (IVD) assays onto the BD MAX platform and ultimately assume responsibility for manufacturing and commercializing the tests globally.
BD Diagnostics – Diagnostic Systems president Tom Polen said the BD MAX System’s content-rich menu and open capability, full automation and standardized workflow will enable laboratories to consolidate and standardize a broad range of molecular tests to build programs that meet both their current and future clinical needs.
